• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双黄酮作为严重急性呼吸综合征冠状病毒潜在的3-糜蛋白酶样蛋白酶(3CLpro)抑制剂。

Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus.

作者信息

Hartini Yustina, Saputra Bakti, Wahono Bryan, Auw Zerlinda, Indayani Friska, Adelya Lintang, Namba Gabriel, Hariono Maywan

机构信息

Faculty of Pharmacy, Sanata Dharma University, Campus III, Paingan, Maguwoharjo, Depok, Sleman 55282, Yogyakarta, Indonesia.

出版信息

Results Chem. 2021 Jan;3:100087. doi: 10.1016/j.rechem.2020.100087. Epub 2020 Dec 25.

DOI:10.1016/j.rechem.2020.100087
PMID:33520632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7832947/
Abstract

3CL protease is one of the key proteins expressed by SARS-Coronavirus-2 cell, the potential to be targeted in the discovery of antivirus during this COVID-19 pandemic. This protein regulates the proteolysis of viral polypeptide essential in forming RNA virus. 3CL protease (3CLpro) was commonly targeted in the previous SARS-Coronavirus including bat and MERS, hence, by blocking this protein activity, the coronavirus should be eradicated. This study aims to review the potency of biflavonoid as the SARS-Coronavirus-2 3CLpro inhibitor. The review was initiated by describing the chemical structure of biflavonoid and followed by listing its natural source. Instead, the synthetic pathway of biflavonoid was also elaborated. The 3CLpro structure and its function were also illustrated followed by the list of its 3D-crystal structure available in a protein data bank. Lastly, the pharmacophores of biflavonoid have been identified as a protease inhibitor, was also discussed. This review hopefully will help researchers to obtain packed information about biflavonoid which could lead to the study in designing and discovering a novel SARS-Coronavirus-2 drug by targetting the 3CLpro enzyme.

摘要

3CL蛋白酶是严重急性呼吸综合征冠状病毒2(SARS-CoV-2)细胞表达的关键蛋白之一,在此次新型冠状病毒肺炎(COVID-19)大流行期间具有作为抗病毒药物靶点的潜力。该蛋白调节形成RNA病毒所必需的病毒多肽的蛋白水解过程。在之前的包括蝙蝠冠状病毒和中东呼吸综合征冠状病毒(MERS)在内的SARS冠状病毒研究中,3CL蛋白酶(3CLpro)通常是靶点,因此,通过阻断该蛋白的活性,冠状病毒应该能够被根除。本研究旨在综述双黄酮作为SARS-CoV-2 3CLpro抑制剂的潜力。综述首先描述了双黄酮的化学结构,接着列出了其天然来源。此外,还阐述了双黄酮的合成途径。同时还展示了3CLpro的结构及其功能,并列出了蛋白质数据库中可获得的其三维晶体结构。最后,还讨论了已被确定为蛋白酶抑制剂的双黄酮药效基团。本综述有望帮助研究人员获取有关双黄酮的全面信息,从而有助于开展针对3CLpro酶设计和发现新型SARS-CoV-2药物的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/d5968600dd2d/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/fe95a26536bf/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/455b90448a34/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/5b5cb0b0e80c/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/53a93901596f/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/d730c965e326/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/a9e69cecb215/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/4c22f0c0ecce/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/d5968600dd2d/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/fe95a26536bf/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/455b90448a34/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/5b5cb0b0e80c/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/53a93901596f/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/d730c965e326/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/a9e69cecb215/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/4c22f0c0ecce/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3136/7832947/d5968600dd2d/gr7_lrg.jpg

相似文献

1
Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus.双黄酮作为严重急性呼吸综合征冠状病毒潜在的3-糜蛋白酶样蛋白酶(3CLpro)抑制剂。
Results Chem. 2021 Jan;3:100087. doi: 10.1016/j.rechem.2020.100087. Epub 2020 Dec 25.
2
Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.基于芹菜素的双黄酮衍生物作为潜在治疗 SARS-CoV-2 病毒蛋白酶(3CLpro)的药物的评价:通过分子对接、分子动力学和量子力学研究。
J Biomol Struct Dyn. 2023 Aug-Sep;41(13):5915-5945. doi: 10.1080/07391102.2022.2098821. Epub 2022 Jul 18.
3
Identification of Novel Drug Candidates for the Inhibition of Catalytic Cleavage Activity of Coronavirus 3CL-like Protease Enzyme.鉴定新型药物候选物以抑制冠状病毒 3CL 样蛋白酶的催化裂解活性。
Curr Pharm Biotechnol. 2022;23(7):959-969. doi: 10.2174/1389201022666210604150041.
4
In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.计算机分析与鉴定新型冠状病毒 SARS-CoV-2 的 3-糜蛋白酶样主蛋白酶的抗病毒香豆素衍生物。
Mol Divers. 2022 Apr;26(2):1053-1076. doi: 10.1007/s11030-021-10230-6. Epub 2021 Jul 2.
5
The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.PGG 和 EGCG 对 SARS-CoV-2 3CL 样蛋白酶的抑制作用。
Biochem Biophys Res Commun. 2022 Feb 5;591:130-136. doi: 10.1016/j.bbrc.2020.12.106. Epub 2021 Jan 6.
6
Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.冠状病毒 3CL 蛋白酶抑制剂保护细胞免受蛋白酶介导的细胞毒性。
J Virol. 2021 Jun 24;95(14):e0237420. doi: 10.1128/JVI.02374-20.
7
3-chymotrypsin-like protease in SARS-CoV-2.SARS-CoV-2 中的 3-糜蛋白酶样蛋白酶。
Biosci Rep. 2024 Aug 28;44(8). doi: 10.1042/BSR20231395.
8
Plant Products as Inhibitors of Coronavirus 3CL Protease.植物产品作为冠状病毒3CL蛋白酶的抑制剂
Front Pharmacol. 2021 Mar 9;12:583387. doi: 10.3389/fphar.2021.583387. eCollection 2021.
9
Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL): an screening of alkaloids and terpenoids from African medicinal plants.冠状病毒 3-糜蛋白酶样蛋白酶(3CL)的潜在抑制剂:来自非洲药用植物的生物碱和萜类化合物的筛选。
J Biomol Struct Dyn. 2021 Jun;39(9):3396-3408. doi: 10.1080/07391102.2020.1764868. Epub 2020 May 18.
10
Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.配体诱导的中东呼吸综合征(MERS)冠状病毒nsp5蛋白酶(3CLpro)二聚化:对nsp5调控及抗病毒药物开发的启示
J Biol Chem. 2015 Aug 7;290(32):19403-22. doi: 10.1074/jbc.M115.651463. Epub 2015 Jun 8.

引用本文的文献

1
Recovery of Proteases and Protease Inhibitors from spp. Cultivated in Amazonian Lignocellulose Wastes.从亚马逊木质纤维素废料中培养的[具体菌种未给出]中回收蛋白酶和蛋白酶抑制剂。
Curr Protein Pept Sci. 2025;26(1):76-88. doi: 10.2174/0113892037297181240605112831.
2
Agathisflavone, a natural biflavonoid that inhibits SARS-CoV-2 replication by targeting its proteases.贝壳杉素,一种天然双黄酮,通过靶向 SARS-CoV-2 的蛋白酶来抑制其复制。
Int J Biol Macromol. 2022 Dec 1;222(Pt A):1015-1026. doi: 10.1016/j.ijbiomac.2022.09.204. Epub 2022 Sep 29.
3
2-Phenoxyacetamide derivatives as SARS-CoV-2 main protease inhibitor: In silico studies.

本文引用的文献

1
Review and analysis of current responses to COVID-19 in Indonesia: Period of January to March 2020.印度尼西亚当前对2019冠状病毒病应对措施的回顾与分析:2020年1月至3月期间
Prog Disaster Sci. 2020 Apr;6:100091. doi: 10.1016/j.pdisas.2020.100091. Epub 2020 Apr 4.
2
Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19.基于超级计算机的集成对接药物发现管道及其在新冠病毒中的应用。
J Chem Inf Model. 2020 Dec 28;60(12):5832-5852. doi: 10.1021/acs.jcim.0c01010. Epub 2020 Dec 16.
3
Malleability of the SARS-CoV-2 3CL M Active-Site Cavity Facilitates Binding of Clinical Antivirals.
2-苯氧基乙酰胺衍生物作为新型冠状病毒主要蛋白酶抑制剂的计算机模拟研究
Results Chem. 2022 Jan;4:100263. doi: 10.1016/j.rechem.2021.100263. Epub 2021 Dec 12.
4
The Future of Leaf Extract as an Herbal Medicine Product.叶提取物作为草药产品的未来。
Molecules. 2021 Nov 17;26(22):6922. doi: 10.3390/molecules26226922.
5
Potential SARS-CoV-2 3CLpro inhibitors from chromene, flavonoid and hydroxamic acid compound based on FRET assay, docking and pharmacophore studies.基于荧光共振能量转移分析、对接和药效团研究,从色烯、黄酮类化合物和异羟肟酸化合物中筛选潜在的新型冠状病毒3C样蛋白酶抑制剂。
Results Chem. 2021 Jan;3:100195. doi: 10.1016/j.rechem.2021.100195. Epub 2021 Sep 20.
6
GC-MS, LC-MS/MS, Docking and Molecular Dynamics Approaches to Identify Potential SARS-CoV-2 3-Chymotrypsin-Like Protease Inhibitors from Roscoe.GC-MS、LC-MS/MS、对接和分子动力学方法鉴定来自 Roscoe 的 SARS-CoV-2 3-糜蛋白酶样蛋白酶抑制剂
Molecules. 2021 Aug 28;26(17):5230. doi: 10.3390/molecules26175230.
SARS-CoV-2 3CL M 活性位点腔的可塑性促进了临床抗病毒药物的结合。
Structure. 2020 Dec 1;28(12):1313-1320.e3. doi: 10.1016/j.str.2020.10.007. Epub 2020 Oct 23.
4
Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL M: insights into enzyme mechanism and drug design.室温X射线晶体学揭示了新冠病毒3CL M中半胱氨酸残基的氧化和反应性:对酶机制和药物设计的见解
IUCrJ. 2020 Sep 21;7(Pt 6):1028-35. doi: 10.1107/S2052252520012634.
5
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.酮基共价抑制剂冠状病毒 3CL 蛋白酶的发现,为 COVID-19 的潜在治疗提供了可能。
J Med Chem. 2020 Nov 12;63(21):12725-12747. doi: 10.1021/acs.jmedchem.0c01063. Epub 2020 Oct 15.
6
Epidemiology, Genomic Structure, the Molecular Mechanism of Injury, Diagnosis and Clinical Manifestations of Coronavirus Infection: An Overview.冠状病毒感染的流行病学、基因组结构、损伤分子机制、诊断及临床表现概述
Indian J Nephrol. 2020 May-Jun;30(3):143-154. doi: 10.4103/ijn.IJN_191_20. Epub 2020 Jun 1.
7
The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.新型冠状病毒病 2019(COVID-19):作用机制、检测和最近的治疗策略。
Virology. 2020 Dec;551:1-9. doi: 10.1016/j.virol.2020.08.011. Epub 2020 Sep 24.
8
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.猫冠状病毒药物可抑制新型冠状病毒的主要蛋白酶并阻断病毒复制。
Nat Commun. 2020 Aug 27;11(1):4282. doi: 10.1038/s41467-020-18096-2.
9
A natural product biflavonoid scaffold with anti-tryptase activity.具有抗胰蛋白酶活性的天然产物二氢黄酮骨架。
Naunyn Schmiedebergs Arch Pharmacol. 2021 Jan;394(1):107-115. doi: 10.1007/s00210-020-01959-2. Epub 2020 Aug 25.
10
Phytochemicals containing biologically active polyphenols as an effective agent against Covid-19-inducing coronavirus.含有具有生物活性的多酚的植物化学物质作为对抗导致新冠肺炎的冠状病毒的有效剂。
J Funct Foods. 2020 Oct;73:104146. doi: 10.1016/j.jff.2020.104146. Epub 2020 Jul 30.